A citation-based method for searching scientific literature

Janet R Vos, Li Hsu, Richard M Brohet, Marian J E Mourits, Jakob de Vries, Kathleen E Malone, Jan C Oosterwijk, Geertruida H de Bock. J Clin Oncol 2015
Times Cited: 16







List of co-cited articles
38 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
37

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
498
31

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
867
31

Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.
Richard M Brohet, Maria E Velthuizen, Frans B L Hogervorst, Hanne E J Meijers-Heijboer, Caroline Seynaeve, Margriet J Collée, Senno Verhoef, Margreet G E M Ausems, Nicoline Hoogerbrugge, Christi J van Asperen,[...]. J Med Genet 2014
56
25

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
25


Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Timothy R Rebbeck, Nandita Mitra, Fei Wan, Olga M Sinilnikova, Sue Healey, Lesley McGuffog, Sylvie Mazoyer, Georgia Chenevix-Trench, Douglas F Easton, Antonis C Antoniou,[...]. JAMA 2015
252
25


Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
18

Variation in BRCA1 cancer risks by mutation position.
Deborah Thompson, Douglas Easton. Cancer Epidemiol Biomarkers Prev 2002
148
18

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
A J Lee, A P Cunningham, K B Kuchenbaecker, N Mavaddat, D F Easton, A C Antoniou. Br J Cancer 2014
134
18

Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
Tara M Friebel, Susan M Domchek, Timothy R Rebbeck. J Natl Cancer Inst 2014
115
18

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
18

Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
Roger L Milne, Antonis C Antoniou. Endocr Relat Cancer 2016
37
18

Breast-cancer risk in families with mutations in PALB2.
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylkäs, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira,[...]. N Engl J Med 2014
483
12

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
12

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
849
12

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Amy P M Finch, Jan Lubinski, Pål Møller, Christian F Singer, Beth Karlan, Leigha Senter, Barry Rosen, Lovise Maehle, Parviz Ghadirian, Cezary Cybulski,[...]. J Clin Oncol 2014
342
12

Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers.
Anouk Pijpe, Peggy Manders, Richard M Brohet, J Margriet Collée, Senno Verhoef, Hans F A Vasen, Nicoline Hoogerbrugge, Christi J van Asperen, Charlotte Dommering, Margreet G E M Ausems,[...]. Breast Cancer Res Treat 2010
50
12


Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.
Janet R Vos, Geertruida H de Bock, Natalia Teixeira, Dorina M van der Kolk, Liesbeth Jansen, Marian J E Mourits, Jan C Oosterwijk. Eur J Cancer 2013
13
15

Cancer variation associated with the position of the mutation in the BRCA2 gene.
Jan Lubinski, Catherine M Phelan, Parviz Ghadirian, Henry T Lynch, Judy Garber, Barbara Weber, Nadine Tung, Douglas Horsman, Claudine Isaacs, Alvaro N A Monteiro,[...]. Fam Cancer 2004
73
12

Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
D Ford, D F Easton, D T Bishop, S A Narod, D E Goldgar. Lancet 1994
12

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
328
12

Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.
S A Gayther, J Mangion, P Russell, S Seal, R Barfoot, B A Ponder, M R Stratton, D Easton. Nat Genet 1997
336
12

Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
S M Domchek, M M Gaudet, J E Stopfer, M H Fleischaut, J Powers, N Kauff, K Offit, K L Nathanson, M Robson. Breast Cancer Res Treat 2010
40
12

Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.
A Smith, A Moran, M C Boyd, M Bulman, A Shenton, L Smith, R Iddenden, E R Woodward, F Lalloo, E R Maher,[...]. J Med Genet 2007
85
12


Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
560
12

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
12

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
12

Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
J L Hopper, M C Southey, G S Dite, D J Jolley, G G Giles, M R McCredie, D F Easton, D J Venter. Cancer Epidemiol Biomarkers Prev 1999
221
12

Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.
A Moran, C O'Hara, S Khan, L Shack, E Woodward, E R Maher, F Lalloo, D G R Evans. Fam Cancer 2012
165
12

Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database.
Pål Møller, Toni T Seppälä, Inge Bernstein, Elke Holinski-Feder, Paulo Sala, D Gareth Evans, Annika Lindblom, Finlay Macrae, Ignacio Blanco, Rolf H Sijmons,[...]. Gut 2018
215
12

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
J P Struewing, P Hartge, S Wacholder, S M Baker, M Berlin, M McAdams, M M Timmerman, L C Brody, M A Tucker. N Engl J Med 1997
12


The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
A C Antoniou, P P D Pharoah, P Smith, D F Easton. Br J Cancer 2004
289
12

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Mary B Daly, Robert Pilarski, Michael Berry, Saundra S Buys, Meagan Farmer, Susan Friedman, Judy E Garber, Noah D Kauff, Seema Khan, Catherine Klein,[...]. J Natl Compr Canc Netw 2017
296
12

Mutations in BRIP1 confer high risk of ovarian cancer.
Thorunn Rafnar, Daniel F Gudbjartsson, Patrick Sulem, Aslaug Jonasdottir, Asgeir Sigurdsson, Adalbjorg Jonasdottir, Soren Besenbacher, Pär Lundin, Simon N Stacey, Julius Gudmundsson,[...]. Nat Genet 2011
239
6

The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.
Wendy L Bridge, Cassandra J Vandenberg, Roger J Franklin, Kevin Hiom. Nat Genet 2005
158
6


Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
Adam N Rosenthal, Lindsay Fraser, Ranjit Manchanda, Philip Badman, Susan Philpott, Jessica Mozersky, Richard Hadwin, Fay H Cafferty, Elizabeth Benjamin, Naveena Singh,[...]. J Clin Oncol 2013
89
6

Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
502
6

Cancer risk of heterozygotes with the NBN founder mutation.
Eva Seemanová, Petr Jarolim, Pavel Seeman, Raymonda Varon, Martin Digweed, Michael Swift, Karl Sperling. J Natl Cancer Inst 2007
55
6

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D Kauff, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat,[...]. N Engl J Med 2002
868
6

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
Sheila Seal, Deborah Thompson, Anthony Renwick, Anna Elliott, Patrick Kelly, Rita Barfoot, Tasnim Chagtai, Hiran Jayatilake, Munaza Ahmed, Katarina Spanova,[...]. Nat Genet 2006
493
6

The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.
Honglin Song, Mine S Cicek, Ed Dicks, Patricia Harrington, Susan J Ramus, Julie M Cunningham, Brooke L Fridley, Jonathan P Tyrer, Jennifer Alsop, Mercedes Jimenez-Linan,[...]. Hum Mol Genet 2014
76
6

Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Chey Loveday, Clare Turnbull, Emma Ramsay, Deborah Hughes, Elise Ruark, Jessica R Frankum, Georgina Bowden, Bolot Kalmyrzaev, Margaret Warren-Perry, Katie Snape,[...]. Nat Genet 2011
320
6

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Susan J Ramus, Honglin Song, Ed Dicks, Jonathan P Tyrer, Adam N Rosenthal, Maria P Intermaggio, Lindsay Fraser, Aleksandra Gentry-Maharaj, Jane Hayward, Susan Philpott,[...]. J Natl Cancer Inst 2015
215
6

Germline RAD51C mutations confer susceptibility to ovarian cancer.
Chey Loveday, Clare Turnbull, Elise Ruark, Rosa Maria Munoz Xicola, Emma Ramsay, Deborah Hughes, Margaret Warren-Perry, Katie Snape, Diana Eccles, D Gareth Evans,[...]. Nat Genet 2012
166
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.